StreetInsider.com News Articles

Form 4 Protagonist Therapeutics For: May 29 Filed by: Waddill William D.

Mon, 01 Jun 2026 18:31:00 -0400

si-local-file:///var/storage/secattach/20260601/26585481.html

Form 4 Protagonist Therapeutics For: May 29 Filed by: Waddill William D.

Mon, 01 Jun 2026 18:31:00 -0400

si-local-file:///var/storage/secattach/20260601/26585481.html

Form 144 Protagonist Therapeutics Filed by: Waddill William D.

Fri, 29 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260529/26575554.html

Form 144 Protagonist Therapeutics Filed by: Waddill William D.

Fri, 29 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260529/26575554.html

Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026

Thu, 28 May 2026 07:05:00 -0400

NEWARK, CA / ACCESS Newswire / May 28, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in two investment bank conferences taking place in June 2026.

2026 Jefferies Global Healthcare Conference; New York, NY - June 2-4, 2026

Format: Fireside Chat

Day/Time: Wednesday, June 3 at 9:55 A.M. ET

Webcast: https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/STGS2oumT8ZPxxrEhwVAR5

Goldman Sachs 47th Annual Global Healthcare Conference 2026; Miami, FL - June 8-10, 2026

Format: Fireside Chat

Day/Time: Wednesday, June 10 at 9:20 A.M. ET

Webcast: https://event.webcasts.com/starthere.jsp?ei=1764366&tp_key=bf1c052870&tp_special=8

If you are interested

Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026

Thu, 28 May 2026 07:05:00 -0400

2026 Jefferies Global Healthcare Conference; New York, NY - June 2-4, 2026

Format: Fireside Chat

Day/Time: Wednesday, June 3 at 9:55 A.M. ET

Webcast: https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/STGS2oumT8ZPxxrEhwVAR5

Goldman Sachs 47th Annual Global Healthcare Conference 2026; Miami, FL - June 8-10, 2026

Format: Fireside Chat

Day/Time: Wednesday, June 10 at 9:20 A.M. ET

Webcast: https://event.webcasts.com/starthere.jsp?ei=1764366&tp_key=bf1c052870&tp_special=8

If you are interested

Wolfe Research Starts Protagonist Therapeutics (PTGX) at Outperform

Thu, 21 May 2026 05:32:38 -0400

(Updated - May 21, 2026 5:32 AM EDT)

Wolfe Research analyst Alexandria Hammond initiates coverage on Protagonist Therapeutics (NASDAQ: PTGX) with a Outperform rating and a price target of $135.00.

The analyst comments "An early stage pipeline with a higher probability of success (PoS) than the industry norm. When you combine biology that's already well-validated, in indications with clear regulatory pathways, and a company's exclusive know-how & focus on peptides, the result is a higher PoS. Here, the proof is in the pudding with Icotyde & rusfertide. And looking forward, PTGX is a better version now than when it invented those molecules,

Wolfe Research Starts Protagonist Therapeutics (PTGX) at Outperform

Thu, 21 May 2026 05:32:38 -0400

(Updated - May 21, 2026 5:32 AM EDT)

Wolfe Research analyst Alexandria Hammond initiates coverage on Protagonist Therapeutics (NASDAQ: PTGX) with a Outperform rating and a price target of $135.00.

Wolfe Research Starts Protagonist Therapeutics (PTGX) at Outperform

Thu, 21 May 2026 05:32:38 -0400

(Updated - May 21, 2026 5:32 AM EDT)

Wolfe Research analyst Alexandria Hammond initiates coverage on Protagonist Therapeutics (NASDAQ: PTGX) with a Outperform rating and a price target of $135.00.

Wolfe Research Starts Protagonist Therapeutics (PTGX) at Outperform

Thu, 21 May 2026 05:32:38 -0400

(Updated - May 21, 2026 5:32 AM EDT)

Wolfe Research analyst Alexandria Hammond initiates coverage on Protagonist Therapeutics (NASDAQ: PTGX) with a Outperform rating and a price target of $135.00.

Form 4/A Protagonist Therapeutics For: May 12 Filed by: PATEL DINESH V PH D

Thu, 14 May 2026 20:07:00 -0400

si-local-file:///var/storage/secattach/20260514/26497360.html

Form 4/A Protagonist Therapeutics For: May 12 Filed by: PATEL DINESH V PH D

Thu, 14 May 2026 20:07:00 -0400

si-local-file:///var/storage/secattach/20260514/26497360.html

Form 4 Protagonist Therapeutics For: May 12 Filed by: PATEL DINESH V PH D

Tue, 12 May 2026 19:28:00 -0400

si-local-file:///var/storage/secattach/20260512/26479844.html

Form 4 Protagonist Therapeutics For: May 12 Filed by: PATEL DINESH V PH D

Tue, 12 May 2026 19:28:00 -0400

si-local-file:///var/storage/secattach/20260512/26479844.html

Form 144 Protagonist Therapeutics Filed by: PATEL DINESH V PH D

Tue, 12 May 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260512/26479538.html

Form 144 Protagonist Therapeutics Filed by: PATEL DINESH V PH D

Tue, 12 May 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260512/26479538.html

Form SCHEDULE 13G Protagonist Therapeutics Filed by: STATE STREET CORP

Tue, 12 May 2026 11:51:00 -0400

si-local-file:///var/storage/secattach/20260512/26475844.html

Form SCHEDULE 13G Protagonist Therapeutics Filed by: STATE STREET CORP

Tue, 12 May 2026 11:51:00 -0400

si-local-file:///var/storage/secattach/20260512/26475844.html

Form 4 Protagonist Therapeutics For: May 07 Filed by: Giraudo Bryan

Mon, 11 May 2026 20:26:00 -0400

si-local-file:///var/storage/secattach/20260511/26471179.html

Form 4 Protagonist Therapeutics For: May 07 Filed by: Giraudo Bryan

Mon, 11 May 2026 20:26:00 -0400

si-local-file:///var/storage/secattach/20260511/26471179.html

BMO Capital Reiterates Outperform Rating on Protagonist Therapeutics (PTGX)

Mon, 11 May 2026 09:22:35 -0400

BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $112.00 price target on Protagonist Therapeutics (NASDAQ: PTGX).

The analyst commented: "Main Character Energy–Momentum Increases Upside Potential for PTGX; Commercial launches and anticipated approvals could enable accelerated clinical diversification and growth for Protagonist. As of March 31, 2026, the company held cash and cash equivalents of $620M, with an anticipated runway through ~2028. Following the recent Icotyde approval (here) and launch, we could see potential additional indication approvals for the product into the decade, and a nearer-term rusfertide approval later this year (Aug. 2026 PDUFA). We continue to like collaboration

Form 144 Protagonist Therapeutics Filed by: Giraudo Bryan

Fri, 08 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260508/26461500.html

Form 144 Protagonist Therapeutics Filed by: Giraudo Bryan

Fri, 08 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260508/26461500.html

Form 144 Protagonist Therapeutics Filed by: Giraudo Bryan

Thu, 07 May 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260507/26455300.html

Form 144 Protagonist Therapeutics Filed by: Giraudo Bryan

Thu, 07 May 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260507/26455300.html